Neovasc Announces Third Quarter Financial Results and Provides Corporate Update
Neovasc Inc. (NVCN) reported third-quarter 2022 revenues of $923,000, marking a 31% year-over-year increase. The company saw strong acceptance of its Reducer product in the UK and France, with France being the largest market. Enrollment in the COSIRA II pivotal trial is on track for completion in the first half of 2024. The company received US outpatient reimbursement effective January 1, 2023. Despite a COVID surge and currency fluctuations, Neovasc maintained a gross margin of 76% but reported a net loss of $6.7 million. Cash reserves stood at $31.3 million.
- Revenues increased by 31% to $923,000 compared to $703,000 in Q3 2021.
- Effective January 1, 2023, received US outpatient reimbursement for the Reducer Therapy.
- Enrollment in the COSIRA II trial expected to complete in the first half of 2024.
- Operating losses were $6.7 million, compared to $6.7 million in Q3 2021.
- Comprehensive losses increased to $8.2 million from $6.9 million in the same quarter last year.
VANCOUVER and MINNEAPOLIS, Nov. 10, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today reported financial results for the third quarter ended September 30, 2022.
Recent Highlights
- Generated revenues of
$923,000 , a quarterly record and a year-over-year increase of31% compared to the third quarter of 2021. - Accelerating acceptance of Reducer in the UK and French markets, with France the largest volume market in the quarter.
- Continued enrollment in the COSIRA II pivotal trial, with enrollment expected to be complete in the first half of 2024 and initial data readout in the second half of 2024.
- In July, 2022, the Company received approval to expand the scope of the COSIRA II trial with a registry to include patients suffering from angina with non-obstructed coronary artery disease, so-called ANOCA patients.
- Released preliminary data at the Transcatheter Cardiovascular Therapeutics conference in September, showing the Reducer’s benefits to ANOCA patients.
- Received US outpatient reimbursement by CMS for the Reducer Therapy, effective January 1, 2023.
“I am pleased to report on the tremendous progress the Neovasc team has made in the third quarter towards advancing our value creation strategies, despite a COVID surge that impacted procedure volumes and currency exchange fluctuations that impacted revenues in the quarter,” said Fred Colen, President and Chief Executive Officer. “Despite these headwinds, Neovasc nevertheless achieved another quarter of record revenues as we continue to benefit from the successes in getting the Reducer reimbursed in the UK, France, and in the US as part of the COSIRA II trial. We now have adequate coding, coverage and payment to support full reimbursement for the Reducer, in the CMS population, for both inpatient and outpatient procedures (effective January 1, 2023), both during the COSIRA-II Clinical Trial, and upon potential commercialization in the United States. Additionally, we have developed the new ICD-10 diagnosis code that became effective October 1, that established “refractory angina” as a condition distinct from other, less severe, forms of angina. Furthermore, we continue to provide leading clinical data, this time demonstrating benefits of the Reducer therapy in yet another refractory angina patient population, currently without good treatment options; in September 2022, we announced preliminary data supporting the benefits of the Reducer therapy to patients with angina and non-obstructive coronary artery disease, so-called ANOCA patients. I look forward to sharing further exciting updates in future quarters.”
Financial Results for the Third Quarter Ended September 30, 2022
Revenues increased by
Total expenses for the three months ended September 30, 2022 were approximately
Operating losses and comprehensive losses for the three months ended September 30, 2022 were
As of September 30, 2022, the company had
As of November 8, 2022, subsequent to the effect of the share consolidations, the Company had 2,746,625 common shares (“Common Shares”) issued and outstanding.
Conference Call and Webcast Information
Interested parties may access the conference call by dialing (800) 458-4121 or (856) 344-9290 (International) and reference Conference ID 7304031. Participants wishing to join the call via webcast should use the link posted on the investor relations section of the Neovasc website at neovasc.com/investors/. A replay of the webcast will be available approximately 30 minutes after the conclusion of the call using the link on the Neovasc website.
About Neovasc Inc.
Neovasc is a specialty medical device company that develops, manufactures, and markets products for the rapidly growing cardiovascular marketplace. Its products include Neovasc Reducer™, for the treatment of refractory angina, which is under clinical investigation in the United States and has been commercially available in Europe since 2015, and Tiara™, a product under clinical investigation for the transcatheter treatment of mitral valve disease. The Company remains committed to the ongoing follow-up of patients in Tiara clinical trials and has paused all other Tiara activities. For more information, visit: www.neovasc.com.
| NEOVASC INC. | ||||||
| Unaudited Condensed Interim Consolidated Statements of Financial Position | ||||||
| (Expressed in U.S. dollars) | ||||||
| September 30, | December 31, | |||||
| 2022 | 2021 | |||||
| ASSETS | ||||||
| Current assets | ||||||
| Cash and cash equivalents | $ | 31,254,368 | $ | 51,537,367 | ||
| Accounts receivable | 1,689,596 | 1,369,455 | ||||
| Finance lease receivable | - | 43,543 | ||||
| Inventory | 1,285,263 | 1,480,077 | ||||
| Prepaid expenses and other assets | 368,766 | 787,734 | ||||
| Total current assets | 34,597,993 | 55,218,176 | ||||
| Non-current assets | ||||||
| Restricted cash | 436,498 | 469,808 | ||||
| Right-of-use asset | 333,708 | 456,339 | ||||
| Property and equipment | 181,219 | 182,041 | ||||
| Deferred loss on 2020 derivative warrant liabilities | 1,598,357 | 4,300,484 | ||||
| Deferred loss on 2021 derivative warrant liabilities | 7,428,944 | 9,898,475 | ||||
| Total non-current assets | 9,978,726 | 15,307,147 | ||||
| Total assets | $ | 44,576,719 | $ | 70,525,323 | ||
| LIABILITIES AND EQUITY | ||||||
| Liabilities | ||||||
| Current liabilities | ||||||
| Accounts payable and accrued liabilities | $ | 3,739,429 | $ | 4,629,163 | ||
| Lease liabilities | 224,195 | 273,145 | ||||
| 2019 Convertible notes | - | 38,633 | ||||
| 2020 Convertible notes | - | 40,587 | ||||
| 2022 Convertible notes | 135,863 | |||||
| Total current liabilities | 4,099,487 | 4,981,528 | ||||
| Non-Current Liabilities | ||||||
| Lease liabilities | 200,725 | 272,652 | ||||
| 2019 Convertible notes | - | 6,548,796 | ||||
| 2020 Convertible notes, warrants and derivative warrant liabilities | 126,355 | 6,088,728 | ||||
| 2021 Derivative warrant liabilities | 57,609 | 405,508 | ||||
| 2022 Convertible notes | 12,029,305 | - | ||||
| Total non-current liabilities | 12,413,994 | 13,315,684 | ||||
| Total liabilities | $ | 16,513,481 | $ | 18,297,212 | ||
| Equity | ||||||
| Share capital | $ | 441,153,987 | $ | 439,873,457 | ||
| Contributed surplus | 42,491,190 | 40,355,952 | ||||
| Accumulated other comprehensive loss | (6,229,804 | ) | (7,885,024 | ) | ||
| Deficit | (449,352,135 | ) | (420,116,274 | ) | ||
| Total equity | 28,063,238 | 52,228,111 | ||||
| Total liabilities and equity | $ | 44,576,719 | $ | 70,525,323 | ||
| NEOVASC INC. | ||||||||||||
| Unaudited Condensed Interim Consolidated Statements of Loss and Comprehensive Loss | ||||||||||||
| For the three and nine months ended September 30, 2022 and 2021 | ||||||||||||
| (Expressed in U.S. dollars) | ||||||||||||
| For the Three Months Ended | For the Nine Months Ended | |||||||||||
| 30-Sep | 30-Sep | |||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||
| REVENUE | $ | 923,311 | $ | 703,420 | $ | 2,352,118 | $ | 1,788,282 | ||||
| COST OF GOODS SOLD | 220,030 | 164,843 | 514,249 | 346,342 | ||||||||
| GROSS PROFIT | 703,281 | 538,577 | 1,837,869 | 1,441,940 | ||||||||
| EXPENSES | ||||||||||||
| Selling expenses | 1,062,454 | 786,366 | 3,276,625 | 2,257,157 | ||||||||
| General and administrative expenses | 2,336,874 | 2,999,003 | 8,477,598 | 13,334,376 | ||||||||
| Product development and clinical trials expenses | 4,044,443 | 3,477,884 | 11,655,659 | 11,840,199 | ||||||||
| 7,443,771 | 7,263,253 | 23,409,882 | 27,431,732 | |||||||||
| OPERATING LOSS | (6,740,490 | ) | (6,724,676 | ) | (21,572,013 | ) | (25,989,792 | ) | ||||
| OTHER (EXPENSE)/INCOME | ||||||||||||
| Interest and other income | 105,412 | 507,775 | 175,030 | 557,529 | ||||||||
| Interest and other expense | (427,207 | ) | (33,551 | ) | (1,166,472 | ) | (352,114 | ) | ||||
| Loss on foreign exchange | (106,316 | ) | (8,162 | ) | (116,124 | ) | (28,400 | ) | ||||
| Unrealized (loss)/gain on warrants, derivative liability warrants | ||||||||||||
| and convertible notes | (28,624 | ) | 1,738,258 | 433,014 | 16,997,651 | |||||||
| Realized loss on exercise or conversion and extinguishment | ||||||||||||
| of warrants, derivative liability warrants and convertible notes | - | (223,747 | ) | (1,845,822 | ) | (2,119,091 | ) | |||||
| Amortization of deferred loss | (1,029,470 | ) | (2,791,494 | ) | (3,271,316 | ) | (7,817,937 | ) | ||||
| (1,486,205 | ) | (810,921 | ) | (5,791,690 | ) | 7,237,638 | ||||||
| LOSS BEFORE TAX | (8,226,695 | ) | (7,535,597 | ) | (27,363,703 | ) | (18,752,154 | ) | ||||
| Tax recovery | - | - | - | 16,128 | ||||||||
| LOSS FOR THE PERIOD | ($ | 8,226,695 | ) | ($ | 7,535,597 | ) | ($ | 27,363,703 | ) | ($ | 18,736,026 | ) |
| OTHER COMPREHENSIVE LOSS FOR THE PERIOD | ||||||||||||
| Fair market value changes in convertible notes due to changes | - | 619,635 | (216,938 | ) | (366,002 | ) | ||||||
| in own credit risk | ||||||||||||
| LOSS AND OTHER COMPREHENSIVE LOSS FOR THE PERIOD | ||||||||||||
| ($ | 8,226,695 | ) | ($ | 6,915,962 | ) | ($ | 27,580,641 | ) | ($ | 19,102,028 | ) | |
| LOSS PER SHARE | ||||||||||||
| Basic and diluted loss per share | ($ | 3.00 | ) | ($ | 2.79 | ) | ($ | 10.03 | ) | ($ | 7.63 | ) |
Forward-Looking Statement Disclaimer
Certain statements in this news release contain forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws that may not be based on historical fact. When used herein, the words “expect”, “anticipate”, “estimate”, “may”, “will”, “should”, “intend”, “believe”, and similar expressions, are intended to identify forward-looking statements. Forward-looking statements may involve, but are not limited to, the enrollment timeline for the COSIRA II pivotal trial, the expectation that the Company’s direct sales team will advance Reducer as a viable treatment for refractory angina in the UK, the expectation that the Company will have an equally strong performance in the fourth quarter of 2022, the expectation that the pause of all activity on the Tiara TA device will not affect ongoing business, the expected benefits of the Reducer therapy, the commitment to the ongoing follow-up of patients in Tiara clinical trials and the growing cardiovascular marketplace. Forward-looking statements are based on estimates and assumptions made by the Company in light of its experience and its perception of historical trends, current conditions and expected future developments, as well as other factors that the Company believes are appropriate in the circumstances. Many factors and assumptions could cause the Company’s actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements, including , without limitation, risks around the Company's ability to continue as a going concern; risks around the Company's history of losses and significant accumulated deficit; risks related to the COVID-19 coronavirus outbreak or other health epidemics, which could significantly impact the Company's operations, sales or ability to raise capital or enroll patients in clinical trials and complete certain Tiara development milestones on the Company's expected schedule; risks relating to the Company's need for significant additional future capital and the Company's ability to raise additional funding; risks relating to the sale of a significant number of Common Shares; risks relating to the possibility that the Company's Common Shares may be delisted from the Nasdaq or the TSX, which could affect their market price and liquidity; risks relating to the Company's conclusion that it did have effective internal control over financial reporting as of December 31, 2021 and 2020 but not at December 31, 2019; risks relating to the Common Share price being volatile; risks relating to the Company's significant indebtedness, and its effect on the Company's financial condition; risks relating to the influence of significant shareholders of the Company over our business operations and share price; risks relating to lawsuits that the Company is subject to, which could divert the Company's resources and result in the payment of significant damages and other remedies; risks relating to claims by third-parties alleging infringement of their intellectual property rights; risks relating to the Company's ability to establish, maintain and defend intellectual property rights in the Company's products; risks relating to results from clinical trials of the Company's products, which may be unfavorable or perceived as unfavorable; risks associated with product liability claims, insurance and recalls; risks relating to use of the Company's products in unapproved circumstances, which could expose the Company to liabilities; risks relating to competition in the medical device industry, including the risk that one or more competitors may develop more effective or more affordable products; risks relating to the Company's ability to achieve or maintain expected levels of market acceptance for the Company's products, as well as the Company's ability to successfully build its in-house sales capabilities or secure third-party marketing or distribution partners; risks relating to the Company's ability to convince public payors and hospitals to include the Company's products on their approved products lists; risks relating to new legislation, new regulatory requirements and the efforts of governmental and third-party payors to contain or reduce the costs of healthcare; risks relating to increased regulation, enforcement and inspections of participants in the medical device industry, including frequent government investigations into marketing and other business practices; risks relating to the extensive regulation of the Company's products and trials by governmental authorities, as well as the cost and time delays associated therewith; risks relating to post-market regulation of the Company's products; risks relating to health and safety concerns associated with the Company's products and industry; risks relating to the Company's manufacturing operations, including the regulation of the Company's manufacturing processes by governmental authorities and the availability of two critical components of the Reducer; risks relating to the possibility of animal disease associated with the use of the Company's products; risks relating to the manufacturing capacity of third-party manufacturers for the Company's products, including risks of supply interruptions impacting the Company's ability to manufacture its own products; risks relating to the Company's dependence on limited products for substantially all of the Company's current revenues; risks relating to the Company's exposure to adverse movements in foreign currency exchange rates; risks relating to the possibility that the Company could lose its foreign private issuer status under U.S. federal securities laws; risks relating to the possibility that the Company could be treated as a "passive foreign investment company"; risks relating to breaches of anti-bribery laws by the Company's employees or agents; risks relating to future changes in financial accounting standards and new accounting pronouncements; risks relating to the Company's dependence upon key personnel to achieve its business objectives; risks relating to the Company's ability to maintain strong relationships with physicians; risks relating to the sufficiency of the Company's management systems and resources in periods of significant growth; risks relating to consolidation in the health care industry, including the downward pressure on product pricing and the growing need to be selected by larger customers in order to make sales to their members or participants; risks relating to the Company's ability to successfully identify and complete corporate transactions on favorable terms or achieve anticipated synergies relating to any acquisitions or alliances; risks relating to conflicts of interests among the Company's officers and directors as a result of their involvement with other issuers; risks relating to future issuances of equity securities by the Company, or sales of Common Shares or conversions of convertible notes, and exercise of warrants, options and restricted stock units by existing security holders, causing the price of the Company's securities to fall; and risks relating to anti-takeover provisions in the Company's constating documents which could discourage a third-party from making a takeover bid beneficial to the Company's shareholders. These risk factors and others relating to the Company are discussed in greater detail in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2021 and in the Management’s Discussion and Analysis for the three and nine months ended September 30, 2022 (copies of which may be obtained at www.sedar.com or www.sec.gov). These factors should be considered carefully, and readers should not place undue reliance on the Company’s forward-looking statements. The Company has no intention and undertakes no obligation to update or revise any forward-looking statements beyond required periodic filings with securities regulators (copies of which may be obtained at www.sedar.com or www.sec.gov), whether because of new information, future events or otherwise, except as required by law.
Contacts
Investors
Mike Cavanaugh
Westwicke/ICR
Email: Mike.Cavanaugh@westwicke.com
Media
Sean Leous
Westwicke/ICR
Email: Sean.Leous@icrinc.com
FAQ
What were Neovasc's revenues for Q3 2022?
What are the key highlights from Neovasc's Q3 2022 press release?
When does Neovasc expect to complete the COSIRA II trial?
What was Neovasc's operating loss in Q3 2022?
When did Neovasc receive US reimbursement for its Reducer therapy?
